Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:53 UTC |
---|
HMDB ID | HMDB0015173 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fenofibrate |
---|
Description | Fenofibrate is only found in individuals that have used or taken this drug. It is an antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. |
---|
Structure | CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1 InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 |
---|
Synonyms | Value | Source |
---|
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester | ChEBI | Finofibrate | ChEBI | FNF | ChEBI | Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate | ChEBI | Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate | ChEBI | Lipantil | ChEBI | Procetofen | ChEBI | Tricor | ChEBI | Antara | Kegg | Lipofen | Kegg | Triglide | Kegg | 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoate 1-methylethyl ester | Generator | Finofibric acid | Generator | Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionic acid | Generator | Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid | Generator | Fenofibric acid | Generator | AZU, fenofibrat | HMDB | Abbott brand OF procetofen | HMDB | Antara micronized procetofen | HMDB | Anto brand OF procetofen | HMDB | Apo fenofibrate | HMDB | Fenofibrat heumann | HMDB | Gen fenofibrate | HMDB | Genpharm brand OF procetofen | HMDB | Heumann brand OF procetofen | HMDB | Heumann, fenofibrat | HMDB | Hexal brand OF procetofen | HMDB | Lichtenstein brand OF procetofen | HMDB | Lipanthyl | HMDB | Livesan | HMDB | Lofibra | HMDB | MTW Fenofibrat | HMDB | MTW-Fenofibrat | HMDB | Normalip | HMDB | Pharmascience brand OF procetofen | HMDB | Procetofene | HMDB | Stada, fenofibrat | HMDB | Supralip | HMDB | Durafenat | HMDB | Apo feno micro | HMDB | Apo-fenofibrate | HMDB | Bouchara brand OF procetofen | HMDB | CiL | HMDB | Fenobeta | HMDB | Fenofibrat hexal | HMDB | Fenofibrat stada | HMDB | Fenofibrat-ratiopharm | HMDB | GNR Pharma brand OF procetofen | HMDB | gate Brand OF procetofen | HMDB | Gen-fenofibrate | HMDB | Knoll brand OF procetofen | HMDB | Lipidil ter | HMDB | MTW Brand OF procetofen | HMDB | Micronized procetofen, antara | HMDB | Novartis brand OF procetofen | HMDB | Nu fenofibrate | HMDB | Procetofen reliant brand | HMDB | Q-Pharm brand OF procetofen | HMDB | Reliant brand OF procetofen | HMDB | Schering plough brand OF procetofen | HMDB | Ratiopharm brand OF procetofen | HMDB | Apo-feno-micro | HMDB | Azupharma brand OF procetofen | HMDB | Fenofibrat azu | HMDB | Fenofibrat abz | HMDB | Fenofibrat FPH | HMDB | Fenofibrat ratiopharm | HMDB | Fénofibrate MSD | HMDB | Hexal, fenofibrat | HMDB | Merck dura brand OF procetofen | HMDB | Novo-fenofibrate | HMDB | Novopharm brand OF procetofen | HMDB | Nu pharm brand OF procetofen | HMDB | Nu-fenofibrate | HMDB | Nu-pharm brand OF procetofen | HMDB | PMS-Fenofibrate micro | HMDB | Phenofibrate | HMDB | Schering-plough brand OF procetofen | HMDB | United drug brand OF procetofen | HMDB | Betapharm brand OF procetofen | HMDB | CT Arzneimittel brand OF procetofen | HMDB | CT-Arzneimittel brand OF procetofen | HMDB | AbZ brand OF procetofen | HMDB | Aliud brand OF procetofen | HMDB | Apotex brand OF procetofen | HMDB | Controlip | HMDB | Debat, fénofibrate | HMDB | Fenofanton | HMDB | Fenofibrat al | HMDB | Fournier brand OF procetofen | HMDB | Fénofibrate debat | HMDB | GNR-Pharma brand OF procetofen | HMDB | Liparison | HMDB | Lipidil | HMDB | Lipidil-ter | HMDB | Novo fenofibrate | HMDB | PMS Fenofibrate micro | HMDB | Procetofen, antara micronized | HMDB | Q Pharm brand OF procetofen | HMDB | Secalip | HMDB | Stadapharm brand OF procetofen | HMDB | Fenofibrat von CT | HMDB |
|
---|
Chemical Formula | C20H21ClO4 |
---|
Average Molecular Weight | 360.831 |
---|
Monoisotopic Molecular Weight | 360.112836867 |
---|
IUPAC Name | propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate |
---|
Traditional Name | antara |
---|
CAS Registry Number | 49562-28-9 |
---|
SMILES | CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1 |
---|
InChI Identifier | InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 |
---|
InChI Key | YMTINGFKWWXKFG-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzophenones |
---|
Direct Parent | Benzophenones |
---|
Alternative Parents | |
---|
Substituents | - Benzophenone
- Aryl-phenylketone
- Diphenylmethane
- Phenoxyacetate
- Phenoxy compound
- Aryl ketone
- Phenol ether
- Benzoyl
- Alkyl aryl ether
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Carboxylic acid ester
- Ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Ether
- Organohalogen compound
- Organic oxygen compound
- Carbonyl group
- Organochloride
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 80.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.00071 g/L | Not Available | LogP | 5.3 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Fenofibrate GC-MS (Non-derivatized) - 70eV, Positive | splash10-00dl-6390000000-5464dc4b809f70f9340d | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fenofibrate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-qTof , Positive-QTOF | splash10-000i-0122900000-4e3cc64221a0b278b61e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-001i-0090000000-f4e7816cd30c8701cce3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-03di-0029000000-60bbd2de375b9b56ec55 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-001i-0190000000-6e83f7c906eaeb363caf | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-0019-0930000000-fccf28abf1a426a6949b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-0900000000-07739caadc1c26a7baaa | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-0900000000-5045a0039b18e3d7dd9a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-1900000000-25a145c2138d34aa4b52 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-03di-0029000000-a98245ce05ccb6a6707e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-001i-0190000000-4e9b3e71fc7960db389e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-0019-0930000000-9d3908b5ee8b5f59218d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-0900000000-1090af5e239a872654d9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-0900000000-5dcab26837d06f9756f8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-000i-1900000000-2663fed5f3ba78d3c7a5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-ITFT , positive-QTOF | splash10-001i-0090000000-4933bea6ce44715c6172 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate , positive-QTOF | splash10-01qi-0595000000-d3c4c1cce3b5e1fbb33f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate , positive-QTOF | splash10-01qi-1594000000-9756f301ee5d44577654 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate , positive-QTOF | splash10-000i-3920000000-91103d7fd9d1063bae9a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate LC-ESI-QFT , positive-QTOF | splash10-0019-0941000000-27e0cd2c4e952b499a9a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 30V, Positive-QTOF | splash10-0019-0970000000-f960f9a0219e1709ee3e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 35V, Positive-QTOF | splash10-0019-0941000000-209b1dce353df6d4c3f7 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 75V, Positive-QTOF | splash10-000i-0900000000-5dcab26837d06f9756f8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 40V, Positive-QTOF | splash10-000i-0900000000-b5b0b2c35e971fbd8662 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 20V, Positive-QTOF | splash10-001i-0090000000-3c45cd011e7c4db69cf8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fenofibrate 10V, Positive-QTOF | splash10-03di-0019000000-250a5f55ce22e370047d | 2021-09-20 | HMDB team, MONA | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01039 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01039 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01039 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 3222 |
---|
KEGG Compound ID | C07586 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Fenofibrate |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 3339 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 5001 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. [PubMed:15124979 ]
- Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. [PubMed:16310551 ]
|
---|